Cindy Shin-Yi Lin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8320280/publications.pdf

Version: 2024-02-01

79 papers	3,630 citations	159525 30 h-index	138417 58 g-index
82 all docs	82 docs citations	82 times ranked	4661 citing authors

#	Article	IF	Citations
1	Chemotherapyâ€induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437.	157.7	547
2	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	4.9	454
3	Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 973-985.	0.9	320
4	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. Oncologist, 2011, 16, 708-716.	1.9	171
5	Clinical evaluation of excitability measures in sensory nerve. Muscle and Nerve, 2001, 24, 883-892.	1.0	141
6	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	3.7	123
7	Axonal changes in spinal cord injured patients distal to the site of injury. Brain, 2006, 130, 985-994.	3.7	96
8	Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 2012, 20, 2959-2967.	1.0	93
9	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxelâ€induced neuropathy. Muscle and Nerve, 2011, 43, 367-374.	1.0	69
10	Association Between Calcineurin Inhibitor Treatment and Peripheral Nerve Dysfunction in Renal Transplant Recipients. American Journal of Transplantation, 2013, 13, 2426-2432.	2.6	69
11	Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Neurology, 2011, 68, 862.	4.9	63
12	Guillain-Barre syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 907-913.	0.9	63
13	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	0.7	63
14	Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity. PLoS ONE, 2011, 6, e18469.	1.1	61
15	Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Frontiers in Neurology, 2019, 10, 898.	1.1	49
16	Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes. Diabetes, 2012, 61, 1592-1598.	0.3	48
17	Rapid and reversible responses to <scp>IVIG</scp> in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. Journal of the Peripheral Nervous System, 2013, 18, 275-296.	1.4	47
18	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 1424-1432.	1.8	47

#	Article	IF	Citations
19	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 2014, 125, 179-185.	0.7	46
20	Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of Neuroimmunology, 2017, 309, 41-46.	1.1	44
21	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2460-2467.	0.7	42
22	Variations in excitability of single human motor axons, related to stochastic properties of nodal sodium channels. Journal of Physiology, 2004, 559, 953-964.	1.3	41
23	After-effects of near-threshold stimulation in single human motor axons. Journal of Physiology, 2005, 564, 931-940.	1.3	40
24	Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 2011, 122, 2336-2344.	0.7	40
25	Exploring the Evolution of Cortical Excitability Following Acute Stroke. Neurorehabilitation and Neural Repair, 2016, 30, 244-257.	1.4	40
26	Adaptation of motor function after spinal cord injury: novel insights into spinal shock. Brain, 2011, 134, 495-505.	3.7	36
27	Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 2011, 134, 3185-3197.	3.7	35
28	Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 2013, 27, 219-229.	1.4	35
29	Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 2014, 137, 2155-2163.	3.7	35
30	Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 78-85.	0.9	33
31	Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 2013, 36, 1272-1277.	4.3	30
32	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 53-59.	1.7	29
33	Elucidating Unique Axonal Dysfunction Between Nitrous Oxide Abuse and Vitamin B12 Deficiency. Frontiers in Neurology, 2019, 10, 704.	1.1	29
34	Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2015, 126, 828-836.	0.7	26
35	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2015, 2, 1916-1922.	2.7	25
36	Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 2013, 591, 273-286.	1.3	24

#	Article	IF	Citations
37	Changes in human sensory axonal excitability induced by focal nerve compression. Journal of Physiology, 2010, 588, 1737-1745.	1.3	23
38	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993.	1.1	23
39	Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. Journal of Neurophysiology, 2015, 113, 3209-3218.	0.9	23
40	Botulinum toxin modulates cortical maladaptation in postâ€stroke spasticity. Muscle and Nerve, 2013, 48, 93-99.	1.0	21
41	Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS ONE, 2017, 12, e0171223.	1.1	21
42	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 2011, 227, 120-127.	2.0	18
43	Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 2012, , .	0.2	18
44	Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. PLoS ONE, 2013, 8, e59055.	1.1	18
45	Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 2010, 126, e734-e739.	1.0	17
46	Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. Muscle and Nerve, 2011, 44, 402-409.	1.0	17
47	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. Clinical Neurophysiology, 2016, 127, 1700-1706.	0.7	17
48	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes, 2017, 66, 1661-1670.	0.3	17
49	Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 2013, 12, 826-834.	1.4	16
50	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218.	1.6	16
51	Activityâ€dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 2011, 16, 159-168.	1.4	14
52	Porphyric neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 613-627.	1.0	14
53	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2014, 49, 858-865.	1.0	14
54	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	2.0	14

#	Article	IF	Citations
55	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2015, 31, 175-182.	1.7	14
56	Early sensory neurophysiological changes in prediabetes. Journal of Diabetes Investigation, 2020, 11, 458-465.	1.1	12
57	Burning pain: axonal dysfunction in erythromelalgia. Pain, 2017, 158, 900-911.	2.0	11
58	Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2636-2642.	0.7	10
59	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. Clinical Neurophysiology, 2017, 128, 93-99.	0.7	10
60	Immuneâ€mediated axonal dysfunction in seropositive and seronegative primary SjÃ¶grenâ€™s syndrome. Annals of Clinical and Translational Neurology, 2020, 7, 819-828.	1.7	10
61	Transynaptic Changes Evident in Peripheral Axonal Function After Acute Cerebellar Infarct. Cerebellum, 2014, 13, 669-676.	1.4	9
62	Sensory axonal dysfunction in cervical radiculopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 640-645.	0.9	9
63	Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment?. Journal of Clinical Oncology, 2011, 29, e553-e554.	0.8	8
64	Nerve Excitability. , 2012, , 345-365.		8
65	Impaired energyâ€dependent processes underlie acute lead neuropathy. Muscle and Nerve, 2012, 46, 954-956.	1.0	8
66	Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 721-725.	1.0	8
67	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 2011, 122, 194-198.	0.7	7
68	The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 2011, 44, 841-841.	1.0	7
69	Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen. Journal of Physiology, 2022, 600, 95-109.	1.3	7
70	Differences in excitability between median and superficial radial sensory axons. Clinical Neurophysiology, 2012, 123, 1440-1445.	0.7	5
71	Altered sensory nerve excitability in fibromyalgia. Journal of the Formosan Medical Association, 2021, 120, 1611-1619.	0.8	3
72	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. Cancer Chemotherapy and Pharmacology, 2011, 67, 1189-1190.	1.1	2

#	Article	IF	Citations
73	Multifocal motor neuropathy: lost in conduction block?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1062-1062.	0.9	2
74	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 2018, 57, 615-621.	1.0	2
75	Differences in nerve excitability properties across upper limb sensory and motor axons. Clinical Neurophysiology, 2022, 136, 138-149.	0.7	2
76	No gain - no pain?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 364-364.	0.9	1
77	Reply: Biomarkers of â€˜acute-onsetâ€™ chronic inflammatory demyelinating polyneuropathy. Brain, 2015, 138, e336-e336.	3.7	0
78	Is Google good enough for medicine?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 915-915.	0.9	0
79	009â€…Axonal excitability properties in dravetâ€™s syndrome reflect effect of loss of sodium channels. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A4.1-A4.	0.9	0